Dompé enrolls first patients in phase 3 trial of Isocyclosporin for atopic keratoconjunctivitis | Optometry Times - Clinical News

Published on December 16, 2025
Isocyclosporin is a dual inhibitor of transient receptor potential cation channel, mucolipin subfamily, member 2 (TRPML2), and calcineurin.
Continue reading on website
Other news

FDA extends Aldeyra's reproxalap PDUFA after requesting additional clinical study report | Optometry Times - Clinical News

December 16, 2025
Aldeyra met with the FDA on December 12, 2025, in which the FDA requested the company submit the CSR from the reproxalap dry eye disease field trial to the NDA.

American Optometric Association

December 17, 2025
Change Agent Scott Gibbons, O.D., shares his thoughts on pediatric eye health and The Myopia Collective. Read more on how The Myopia Collective harnesses advocacy efforts to drive meaningful...